The global transdermal skin patches market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The growing funding and investments for drug development and new launches boost the growth of market growth. For instance, in September 2021, ImQuest Biosciences has announced the launch of an antiretroviral (ARV) transdermal delivery patch. Simialry, in Feb 2020, the US FDA approved the Contraceptive Patch known as Twirla Transdermal System by Agile Therapeutics Inc. Twirla (levonorgestrel and ethinly estradiol) is a combination of the female hormones progestin and estrogen which is used as a method of contraception for use in women of reproductive potential with a BMI less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
Browse the full report description of “Global Transdermal Skin Patches Market Size, Share and Trends Analysis Report, By Type (Single-Layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Matrix, and Others), By Application (Pain Relief, Smoking Reduction and Cessation Aid, Overactive Bladder, Hormonal Therapy, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/transdermal-skin-patches-market
Clinical trials of various drugs are underway, and this would be a positive impact on the growth of the market in the future. With new systems in the transdermal drug delivery technique, there has been a continuous rise in the market. As transdermal patches offer many benefits over traditional drug delivery such as the pill, powder, or liquid medication. One of the most important and fundamental benefits of using patches is direct to bloodstreams delivery while bypassing the liver’s metabolic activity. This method of drug delivery is very much beneficial for the patients who are suffering from hepatic disorders as stress to the liver as it is simply bypassed. Transdermal patches can be designed to provide prolonged and controlled release of certain drugs which can be convenient for pain relief drugs, nicotine, and hormone products. For instance, the granisetron transdermal system is a transdermal patch used to treat chemotherapy-induced nausea and vomiting in a regulated way.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
? By Type
? By Application
• Regions Covered-
? North America
? Europe
? Asia-Pacific
? Rest of the World
• Competitive Land-. Novartis International AG, Teva Pharmaceuticals USA Inc., The 3M Co., Mylan N.V., Pfizer Inc., and many more.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Transdermal Skin Patches Market Report by Segment
By Type
By Applications
Global Transdermal Skin Patches Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/transdermal-skin-patches-market